Objectives: The optimal duration of antibiotic therapy for uncomplicated Gram-negative bacteraemia remains undefined. Our objective was to compare clinical outcomes of receiving short (7 -10 days) versus prolonged (.10 days) durations of antibiotic therapy for children with uncomplicated Gram-negative bacteraemia.
Introduction
Gram-negative bacteraemia is a significant contributor to morbidity and mortality in children with underlying medical conditions, 1 particularly those requiring central venous catheters. 2 The optimal duration of antibiotic therapy for Gram-negative bacteraemia in children, however, remains unclear. The Infectious Diseases Society of America (IDSA) guidelines for Gram-negative bacteraemia (in both children and adults) suggest a duration of therapy between 7 and 14 days, but the strength of the recommendation and quality of the evidence are graded as poor (C-III). 3 Prolonging antibiotic exposure has been associated with the emergence of antimicrobial resistance, Clostridium difficile infections (CDIs) and candidal superinfections. 4 -7 Consequently, judicial use of antibiotic therapy is paramount to optimizing clinical outcomes of children while limiting potential unintended negative consequences.
A recent meta-analysis evaluating 155 patients from 24 randomized controlled trials showed that bacteraemia (due to both Gram-positive and Gram-negative organisms) could be treated with antibiotics for ,7 days without compromising patient outcomes. 8 However, .90% of included patients had bacteraemia as a consequence of community-acquired pneumonia or pyelonephritis and none of the included studies enrolled patients with catheter-associated bacteraemia. There have been no studies on the optimal duration of antibiotics for Gram-negative bacteraemia in the paediatric population outside the neonatal period. 9, 10 The objective of our study was to estimate the effect of the duration of antibiotic therapy on clinical outcomes of children with uncomplicated Gram-negative bacteraemia.
Methods

Setting and patients
We conducted a retrospective cohort study of children ≥2 months of age to 18 years of age hospitalized with Gram-negative bacteraemia at the 205 bed Johns Hopkins Hospital from January 2002 until December 2012. Children met eligibility criteria if they: (i) received appropriate antibiotic therapy (based on ultimate in vitro antibiotic susceptibility results) within 24 h of the time the first positive blood culture was obtained; (ii) received at least 7 days of appropriate culture-directed therapy (as this is the minimal amount of therapy recommended by the IDSA for uncomplicated Gram-negative bacteraemia); and (iii) had bacteraemia due to Enterobacteriaceae, Pseudomonas spp. or Acinetobacter baumannii. Children coinfected with Grampositive bacteraemia or yeast were excluded. Children were also excluded if they had profound neutropenia [absolute neutrophil count (ANC) ,100/ mm 3 ], as profoundly neutropenic children in our institution routinely receive prolonged antibiotic courses until their ANCs increase. 11 Additionally, children with infective endocarditis, suppurative thrombophlebitis, CNS infection, osteomyelitis or deep-seated undrained abscesses were excluded since they would be expected to receive prolonged courses of antibiotics.
This study was approved by the Johns Hopkins University Institutional Review Board with a waiver of informed consent.
Data collection
Demographic and clinical characteristics of children with Gram-negative bacteraemia meeting eligibility criteria were retrieved from electronic medical records. The following variables were collected: age, gender, preexisting medical conditions, lowest ANC on the day the first positive blood culture was obtained, likely source of bacteraemia, microorganisms isolated from blood and associated antibiotic susceptibility patterns, duration of bacteraemia, duration of hospital stay prior to the first positive blood culture, antibiotic use, the presence of a central line at the time the first positive blood culture was obtained and central line status daily for the duration of therapy. The following were documented on the first day of bacteraemia: highest paediatric risk of mortality (PRISM) III score, admission to the intensive care unit, presence of mechanical ventilation and vasopressor requirement. The PRISM III score is a predictor of mortality in children that includes 17 physiological variables that have been previously validated. 12 
Exposures and outcomes
The primary exposure was duration of antibiotic therapy dichotomized at 10 days: 7 -10 days was defined as short duration and .10 days as Children were considered immunocompromised if they were infected with HIV, received at least 2 mg/kg steroids for ≥14 days, received chemotherapy within the past 6 months, received a bone marrow transplant within the past 2 years, received a solid organ transplant in the past or if they were currently receiving immunomodulatory therapy.
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prolonged duration. Ten days was selected as a cut-off point after exploratory data analysis showed that short-course therapy clustered around 10 days of antibiotic treatment. Antibiotic treatment duration was also analysed as a continuous variable. The primary outcome was bacteraemic relapse, defined as a positive blood culture with the same organism within 30 days after discontinuing antibiotic therapy for the initial episode of bacteraemia. Additional outcomes included 30 day all-cause mortality and incident candidaemia or CDI during the follow-up period (onset of bacteraemia until 30 days after discontinuation of antibiotics).
Statistical analyses
Decisions concerning the duration of antibiotic therapy for Gram-negative bacteraemia are likely influenced by a number of prognostic factors and can result in selection bias with regard to the number of days of antibiotic therapy prescribed. 4 To limit bias while assessing the impact of antibiotic duration on clinical outcomes, we used propensity score matching to ensure similarity of patients in the comparator groups. Propensity scores were estimated in a multivariable logistic regression model in which the dependent variable was a binary indicator of antibiotic duration. Covariates used to generate propensity scores included age, PRISM III score, ICU admission, pressors or mechanical ventilator use, ANC, immunocompromised status, presence of pseudomonal bacteraemia, primary focus of bacteraemia, use of combination therapy (b-lactam and aminoglycoside) and presence of a central line on day 1 of antibiotic therapy and a retained central line at the termination of antibiotic therapy. We performed 1: 1 nearest neighbour matching without replacement with a calliper width of 0.10. After propensity score matching, covariate values in the short and prolonged duration groups were tested for balance using standardized mean biases. Paired comparisons were performed using McNemar's test for categorical variables and the Wilcoxon signed rank test or paired t-test for continuous variables. Cox proportional hazards modelling was used to estimate the unadjusted hazard ratio and associated 95% CI for potential risk factors of microbiological relapse and secondary outcomes in the matched pairs. The proportional hazards assumption was tested by graphically inspecting complementary log-log plots for each variable. To increase precision, variables with P values ,0.20 in univariable analysis were included in a multivariable model evaluating the risk of microbiological relapse for children treated with short versus prolonged courses of antibiotics. For all tests, twosided P values of ,0.05 were considered statistically significant. Data were analysed using Stata, version 12.0 (Stata Corp., College Station, TX, USA).
Results
There were 170 matched pairs of children in each treatment group and the groups were well balanced with regard to baseline characteristics ( Table 1) . Distributions of antibiotic agents prescribed and microorganisms identified were also similar (Tables 2 and 3 ). The median duration of therapy was 10 days (IQR 10-10 days) and 14 days (IQR 14 -17 days) in the short course and prolonged course groups, respectively (Figure 1 ).
There were 11 deaths amongst matched children, 6 and 5 in the short and long duration groups, respectively (OR 1.12; 95% CI 0.96-1.21); these children were excluded from the bacteraemic relapse analysis as death was considered a competing risk. Of note, half of all deaths in children with Gram-negative bacteraemia from 2002 to 2012 in our institution occurred in the first 7 days (excluded from analysis).
Primary outcome
Thirty-seven children had a bacteraemic relapse within the follow-up period (10.9%), with a median time to relapse after discontinuation of antibiotic therapy of 13 days. Central line retention (hazard ratio 31.63; 95% CI 7.60-131.56, P,0.001) and polymicrobial bacteraemia (hazard ratio 2.36; 95% CI 1.08-5.17, P ¼ 0.03) were risk factors for microbiological relapse. A prolonged duration of antibiotic therapy did not reduce the risk of bacteraemic relapse compared with shorter durations, even after adjusting for central line retention and polymicrobial bacteraemia (adjusted hazard ratio 0.67; 95% CI 0.35-1.27) ( Table 4 and Figure 2) . Similarly, Park et al.
each additional day of therapy was not protective against relapse (adjusted hazard ratio 0.99 per additional day; 95% CI 0.92 -1.03). Among 133 children with central lines retained during therapy, 35 experienced a relapse (26.3%) whereas only two relapses occurred (1.0%) among 205 children experiencing central line removal during therapy or without central lines at the onset of bacteraemia (P,0.001). The risk of microbiological relapse was similar for children who experienced central line removal (or never had a central line) regardless of whether 7-10 or .10 days of antibiotic therapy was prescribed (hazard ratio 1.01; 95% CI 0.06-16.2, P¼0.99) (Figure 3) . Among those children who had their central lines retained, however, the risk of relapse was reduced with a longer duration of therapy, but the reduction in risk did not reach statistical significance (hazard ratio 0.57; 95% CI 0.29-1.13, P¼0.11).
Secondary outcomes
Among the 340 matched patients, 21 candidaemia episodes were identified during the follow-up period. There were 6 (3.5%) and 15 (8.8%) episodes in the short duration and long duration groups, respectively (hazard ratio 2.44; 95% CI 0.97-6.19, P¼0.07). There were only three episodes of CDI among matched patients; two and one in the short and prolonged antibiotic treatment groups, respectively.
Discussion
Our study suggests that children treated with 7 -10 days of therapy for Gram-negative bacteraemia do not have an increased risk of bacteraemic relapse compared with children receiving .10 days of therapy, but shorter courses of antibiotics may be protective against the development of candidaemia.
Studies on the optimal duration of antibiotic therapy for Gramnegative bacteraemia are lacking, leaving uncertainty as to how long antibiotics should be continued. Currently, the IDSA guidelines recommend 7 -14 days of therapy for uncomplicated Gramnegative bacteraemia. 3 However, the authors acknowledge that they were unable to recommend a single preferred treatment duration because of a lack of clinical studies comparing various durations. There is considerable variability in durations of therapy prescribed for Gram-negative bacteraemia, ranging from ,7 days to well over 14 days, as observed in a 2003 survey of prescribers. 13 The authors of the study concluded 'The wide variability in antibiotic prescribing patterns suggests an urgent need to produce high-quality evidence to identify optimal antibiotic prescribing policies for bacteraemia'. 13 Unfortunately, minimal progress has been made since 2003. A meta-analysis from 2011 that included 24 randomized controlled studies showed that bacteraemia could be treated with ,7 days of antibiotics compared with 7-21 days of treatment without compromising patient outcomes. 8 However, a minority of patients had Gram-negative bacteraemia, and of those patients infected with Gram-negative organisms the vast majority were adults with a urinary source. None of the included patients had Gram-negative bacteraemia as the result of an indwelling catheter.
While uncertainty about the optimal antibiotic duration for uncomplicated Gram-negative bacteraemia exists, the harmful effects of prolonged antibiotic therapy are well established.
14 The emergence of drug-resistant organisms puts the host at risk of subsequent serious and difficult-to-treat infections. 15 -20 Additionally, Duration of therapy 783 JAC perturbations in the gastrointestinal flora from prolonged antibiotic exposure allow organisms like yeast and C. difficile to flourish, leading to additional morbidity. 21 -23 In our cohort, children with Gram-negative bacteraemia who failed to have their central lines removed had a 31-fold greater risk of a microbiological relapse within 30 days of discontinuing antibiotics compared with children who underwent central line removal. All but two microbiological relapses were observed in children whose central lines were retained during their treatment course. Children with retained central lines had a significantly higher risk of relapse than children who underwent line removal even if they received prolonged antibiotic therapy, providing further evidence for the need for line removal.
There are some limitations to consider with our study. This was a single-centre study conducted at a tertiary referral centre, potentially limiting the generalizability of our findings. In our study, 96% of the children had one or more comorbid conditions and the most common source of bacteraemia was central lines. Therefore, the results of our study should be interpreted in the context of similar patient populations. However, if 7 -10 days of therapy are sufficient for our population, perhaps even shorter durations of therapy may suffice for relatively healthier children without indwelling hardware or underlying medical conditions. Secondly, this study is a retrospective, observational study. We implemented propensity score matching to ensure comparability between the treatment groups. Although our baseline characteristics were well balanced between the groups after matching on propensity scores, we cannot exclude the possibility of additional unmeasured confounding factors that could influence the exposures and outcomes. By limiting inclusion to patients who were similar across a number of variables in both groups, the incorporation of propensity score matching and subsequent trimming to ensure balance may have compromised the generalizability of our findings to severely ill patients.
In conclusion, our study demonstrates that antibiotic therapy for 7 -10 days is as effective as longer antibiotic courses for uncomplicated Gram-negative bacteraemia in children. Furthermore, shorter courses may reduce harmful consequences of prolonged antibiotic exposure including candidaemia. This work builds upon existing data showing that timely removal of central lines is of paramount importance in reducing the risk of microbiological relapse. Our findings need to be repeated in a larger, multicentre and preferably randomized study.
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